The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 10, 2020

Filed:

Aug. 24, 2016
Applicants:

Glaxosmithkline Biologicals S.a., Rixensart, BE;

Janssen Pharmaceuticals, Inc., Titusville, NJ (US);

Inventors:

Jan Theunis Poolman, Haarlem, NL;

Bert Jacquemyn, Mechelen, BE;

Darren Robert Abbanat, Cornwall, NY (US);

Patricia Ibarra Yon, Solothurn, CH;

Peter Wilhelmus Maria Hermans, Huissen, NL;

Michael Thomas Kowarik, Zurich, CH;

Michael Lukas Wetter, Zurich, CH;

Stefan Jochen Kemmler, Zurich, CH;

Micha Andres Häuptle, Zurich, CH;

Veronica Gambillara Fonck, Meilen, CH;

Manuela Mally, Watt, CH;

Assignees:

GlaxoSmithKline Biological S.A., Rixensart, BE;

Janssen Pharmaceuticals, Inc., Titusville, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/108 (2006.01); A61K 47/64 (2017.01); A61P 31/04 (2006.01); A61K 39/385 (2006.01); C08B 37/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0258 (2013.01); A61K 39/385 (2013.01); A61K 47/646 (2017.08); A61K 47/6415 (2017.08); A61P 31/04 (2018.01); C08B 37/0063 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55583 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6087 (2013.01); A61K 2039/70 (2013.01); Y02A 50/474 (2018.01);
Abstract

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic(ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates ofpolysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of(EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.


Find Patent Forward Citations

Loading…